


PHARMACEUTICAL PRODUCTS LIABILITY LAW FIRM OF THE YEAR IN WASHINGTON DC, US / HIGH STAKES LITIGATION LAW FIRM OF THE YEAR IN WASHINGTON DC, US

Hollingsworth LLP

Donald W Fowler Managing Partner

Tel: +1 202.898.5800 dfowler@hollingsworthllp.com www.hollingsworthllp.com



All of its lawyers specialize in complex trial and appellate work. The majority of Hollingsworth LLP's work is for corporate clients in the areas of pharmaceutical products, toxic torts and products liability, environmental, insurance, federal claims, financial institutions, government contracts, medical devices, and white collar defense. The Firm is called upon to solve its clients' toughest litigation problems nationwide and, in consequence, it regularly has the lead in landmark cases and on cutting-edge litigation theories and defenses.



The Firm is not run by committees insulated by layers of bureaucracy. Litigation team leaders make case-related decisions on a case-by-case basis, and the Firm's managing partners quickly make administrative decisions on a firm-wide basis. Hollingsworth LLP promotes diversity in the hiring of its accomplished lawyers. In February 2014, the Firm was selected by the Minority Corporate Counsel Association (MCCA) as one of three finalists in the Mid-Atlantic Region for the 2014 Thomas L. Sager Award.

Success for clients is the best way to improve market position, and 2016 continues Hollingsworth LLP's long string of successes. It scored impressive victories for a diverse group of major clients in a wide range of legal areas and arenas - demonstrating that victories come in a variety of ways. For example, the Firm successfully resolved for a pharmaceutical client a 21-year-old case that had the potential for a multi-million dollar judgment for the plaintiff; achieved summary judgment for a \$2 million-plus cost award on an insurance matter; and obtained a favorable conclusion to parallel state and federal investigations into a client's alleged false advertising under the Maryland Consumer Protection Act and federal mail fraud statutes. The California Supreme Court granted a client of the Firm its petition for review of a California Court of Appeal opinion, which had relied upon Conte v. Wyeth (2008) 168 Cal. App. 4th 89 in holding that the client could be held liable as a prior manufacturer of a brand drug for injuries allegedly caused years later by a generic version of the drug. Such grant of review is rare.